This compound, known as WIN 35428 (β-CFT), is a potent dopamine reuptake inhibitor widely used in neuroscience research and pharmaceutical development. It acts as a radioligand precursor for imaging dopamine transporters (DAT) in the brain, critical for studying Parkinson’s disease, addiction, and mood disorders. Its high selectivity for DAT makes it a key tool in in vivo SPECT/PET imaging and in vitro binding assays. Additionally, it serves as a pharmacological probe to investigate dopamine signaling pathways and evaluate potential psychostimulant or therapeutic candidates targeting the dopaminergic system. It is strictly for research use only and not approved for human or veterinary medicine.

GHS Classification: GHS06 (Toxic); GHS08 (Health Hazard) Hazard Statements: H301 (Toxic if swallowed); H311 (Toxic in contact with skin); H331 (Toxic if inhaled); H317 (May cause an allergic skin reaction); H361 (Suspected of damaging fertility or the unborn child) Precautionary Statements: P261, P264, P270, P280, P301+P310, P302+P352, P304+P340 This compound is highly toxic; acute toxicity (oral LD50 <500 mg/kg in rats). Skin/eye contact may cause severe irritation, allergic reactions, or systemic toxicity. Inhalation of dust may trigger respiratory distress. It is a suspected reproductive toxin; avoid exposure during pregnancy. Handle only in a fume hood with nitrile gloves, safety goggles, and a respirator. Store locked away, separate from food/feed. Dispose as hazardous waste per local regulations.